Floatz Rating
B57/100
Confidence
Indicative
Sponsor
University of Michigan Rogel Cancer Center
Modality
vaccine
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00405327CT.gov A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Wilms Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dendritic Cell Tumor Cell Lysate Vaccine (this asset) | University of Michigan Rogel Cancer Center | P2 | B · 57 |
| (+)-Vincristine | Centre Oscar Lambret | P2 | BB |
| Adriamycin | Children's National Research Institute | P2 | BB |
| Itraconazole | Samsung Medical Center | P4 | BB |
| Irinotecan | Centre Oscar Lambret | P2 | BB |
| Cyclophosphamide | St. Jude Children's Research Hospital | P2 | BB |
| Nivestim | Barbara Ann Karmanos Cancer Institute | P3 | BB |
| Etoposide | Centre Oscar Lambret | P2 | BB |
| Calcium Phosphate | Children's Oncology Group | P3 | BB |
+42 more in the Wilms Tumor cohort
Other indications for Dendritic Cell Tumor Cell Lysate Vaccine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuroblastoma | — | P2 | B · 57 |
| Sarcoma | — | P2 | CCC · 54 |
| Glioblastoma | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dendritic Cell Tumor Cell Lysate Vaccine in Wilms Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dendritic-cell-tumor-cell-lysate-vaccine-wilms-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →